Prostate News Archive
01-Mar-2009
Ascenta Therapeutics Announces Positive Preliminary Results With AT-101 In Docetaxel Refractory Prostate Cancer (Medical News Today)
Ascenta Therapeutics announced positive preliminary results from its Phase II study of AT-101 in combination with docetaxel and prednisone (D/P) in men with docetaxel refractory, castrate resistant prostate cancer (CRPC) at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium in Orlando, FL. FDA calls Glaxo ad for prostate drug 'misleading' (San Francisco Chronicle)
A marketing campaign for a GlaxoSmithKline prostate drug has drawn complaints from federal regulators, who said the space-themed advertisement is misleading. The British drugmaker's Avodart capsules treat symptoms of enlarged prostate, including frequent... FDA Says Glaxo Prostate Drug Ad Misleads (TheStreet.com)
The FDA says an ad for Glaxo's prostate drug Avodart makes false statements UIC receives $3 million to study prostate cancer risk factors (EurekAlert!)
( University of Illinois at Chicago ) Researchers at the University of Illinois at Chicago's Institute for Health Research and Policy have been awarded a five-year, $3 million grant from the National Cancer Institute to study the link between body fat and prostate cancer progression.
Back to Prostate News Archive
